

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting –March 13, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. February 14, 2013 DUR Minutes – Vote
 - B. February 14, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for February 2013
 - B. Pharmacy Help Desk Activity for February 2013
 - C. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Chronic Obstructive Pulmonary Disease Medications – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

6. **Action Item - Vote to Prior Authorize Select Oral Corticosteroid Medications – See Appendix D.**
 - A. COP Recommendations
 - B. Utilization Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Diabetes Medications and 30 Day Notice to Prior Authorize Juvisync[®], Bydureon[®], Jentaduetto[®], Janumet XR[®], Nesina[®], Kazano[®], and Oseni[®] – See Appendix E.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. Cost Comparisons
 - F. COP Recommendations
 - G. Utilization Details
 - H. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

8. **Action Item –Annual Review of Anticoagulant Medications and 30 Day Notice to Prior Authorize Eliquis[®] – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - D. Prior Authorization Review
 - E. Market News and Update
 - F. COP Recommendations
 - G. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Kuvan[®] – See Appendix G.**
 - A. Introduction and Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Moore, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Gattex[®] – See Appendix H.**
 - A. Introduction and Product Summary
 - B. Cost Comparison
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
 - A. Fiscal Year 2012 Review
 - B. New Product Reviews
 - C. Annual Reviews
13. **Adjournment**